HEALTHCARE UPDATE
FDA Grants Accelerated Approval for a Biomarker-Defined Rectal Cancer Treatment
The FDA granted accelerated approval to dostarlimab (Jemperli) on October 19, 2026 for adults with stage II or III locally advanced rectal cancer classified as MSI-H or dMMR.
A Decision for a Specific Patient Group
These biomarkers describe how a tumor repairs DNA. Eligibility requires an FDA-authorized test. The decision concerns this defined group of patients.
The FDA said partner regulators were still reviewing applications. US approval does not establish access or insurance coverage elsewhere.
Sources: [1]
Preparing for a Specialist Review
For a second-opinion request, organize the pathology and biomarker reports, imaging, and existing treatment plan. Your treating team should assess what the announcement means for your care.
Sources and data notes
- FDA: accelerated approval of dostarlimab for locally advanced rectal cancer
Event October 19, 2026; official announcement and dated approvals index checked October 20. Record-preparation wording is our editorial interpretation. No dosing or response-rate claims republished.
Published by China Heal Plus. General information, not an individual medical assessment. Inclusion of a hospital or physician does not imply a partnership or endorsement of our service.